Clinical trial NCT06072560: Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain
Official title: Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Pain
Pain Syndrome
Pain, Chronic
Chronic Pain
Chronic Pain Syndrome
Back Pain
Lower Back Pain
Lower Back Pain Chronic
Keywords: Adezunap
Pain Therapy
Pain
Pain Syndrome
Chronic Pain
Chronic Pain Syndrome
Back Pain
Chronic Back Pain
Lower Back Pain
Lower Back Pain Chronic
THC
Tetrahydrocannabinol
Delta-9-Tetrahydrocannabinol
Cannabis
Cannabinoids
Lead sponsor: Apurano Pharmaceuticals GmbH
Sponsor class: INDUSTRY
First posted: 2023-10-10
Enrollment: 558
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Over the last years a rising medical need for treatment of chronic pain was identified. Based on previous findings indicating the pain modulating effects of cannabinoids in chronic pain disorders, this clinical trial investigates the efficacy and tolerability of the THC-focused nano endocannabinoid system modulator AP707 in patients with chronic back pain disorders. Patients receive AP707 or placebo over the course of 14 weeks as an add-on to the standard of care. Changes in pain intensity, quality of life and sleep and others measures are monitored through different scales to assess the efficacy of AP707 in patients with chronic back pain.


Eligibility criteria: Inclusion Criteria:

1. Signed and dated informed consent form
2. Patients with chronic back pain since at least 3 months
3. Female and male patients (\> 18 years)
4. Patients with more than 1 year life expectancy
5. Patients with optimized sCPT on study entry as defined in section 3.1.1 and section 3.1.3 of the study protocol
6. Willingness of study patients of both sexes to use reliable contraception during study participation and for three months after taking the last study medication
7. Good command of German language, in order to understand questionnaires in German
8. Current moderate to severe pain with pain intensity \> 5 on Numeric Rating Scale (NRS, 0 - 10) and thus an existing need for further pain therapy
9. Completed QUISS (Quantification Inventory for Somatoform Syndromes) questionnaire with 45 or less score points
10. Completed painDETECT questionnaire with 20 or more score points

Exclusion Criteria:

1. Medical history of hypersensitivity or intolerance to the investigational product or its ingredients or to ingredients of similar chemical structure
2. Known intolerance to cannabinoids or cannabis products.
3. Participation in another clinical trial within the last four weeks prior to inclusion.
4. Pregnant or nursing women (as excluded by pregnancy testing at visit 1).
5. Other medical conditions that do not allow the trial subject to appraise the nature, scope, and potential consequences of the clinical trial
6. Indications that the trial subject is unlikely to comply with the study protocol (e.g., unwillingness to cooperate)
7. Known use of medicinal cannabis products within the last 8 weeks
8. Active malignant tumor disease, tumor pain, or other dominant severe pain other than that of the study indication
9. Known history of severe liver or kidney diseases
10. Known history of severe cardiovascular disease
11. Known history of or acute mental illness such as severe depression, psychosis, bipolar disorder, mania, anxiety, or obsessive-compulsive disorder
12. Known history of addictive disease (e.g., alcohol, medication, drug addiction)
13. Answered during Screening less than 12 times of 18 the pain intensity (NRS) inquiry
14. Laboratory liver values: Alanine aminotransferase (ALT, GPT) \> 3 x ULN (Upper Limit of Normal range), Aspartate aminotransferase (AST, GOT) \> 3 x ULN, Alkaline phosphatase (AP) \> 2.5 x ULN, and for bilirubin \> 1.5 x ULN
15. Laboratory renal value: Serum creatinine \> 1.5 ULN

Primary outcomes:
measure: Change in pain level on the Numeric Rating Scale (NRS, 0-10) between baseline and at treatment week 14 (end of first treatment phase) in comparison of study arm 1 (verum) and study arm 2 (placebo)
timeFrame: Once daily in week 4 and 14
Secondary outcomes:
measure: Change in the pain score of the Neuropathic Pain Symptom Inventory (NPSI) questionnaire between baseline and at treatment week 14 in comparison of study arm 1 (verum) and study arm 2 (placebo)
timeFrame: Week 1 and 14
measure: Change in pain level on the Numeric Rating Scale (0-10) between baseline and in treatment week 5 and 11 in comparison of study arm 1 (verum) and study arm 2 (placebo)
timeFrame: Several times weekly in week 4, 5 and 11
measure: Responder analysis for endpoints 1) for treatment week 14
timeFrame: Week 14
measure: Change in sCPT (percentage of change in dosage and percentage of change in combination of analgesic measures) in both study arms from start to week 14
timeFrame: Week 14
measure: Change in pain-related impairment according to von Korff et al. from start to week 14
timeFrame: Week 1 and 14
measure: Change in psychological distress using Depression Anxiety Stress Scales Short Form (DASS-21) questionnaire from start to week 14
timeFrame: Week 1 and 14
measure: Change of Patient Global Impression of Change (PGIC) from start to week 14
timeFrame: Week 14
measure: Change in quality of life using the Veterans RAND (VR-12) questionnaire from start to week 14
timeFrame: Week 1 and 14
measure: Change in sleep quality using the Regensburg Insomnia Scale (RIS) from start to week 14
timeFrame: Week 1 and 14
measure: Change in pain score of the Brief Pain Inventory - Short Form (BPI-SF) questionnaire from start to week 14
timeFrame: Week 1 and 14
measure: Area under NRS-curve until treatment week 5, 11 and 14
timeFrame: Week 5, 11 and 14
measure: Change in VR-12 components (physical component summary PCS, mental component summary MCS) from start to week 14
timeFrame: Week 1 and 14
measure: Number of patients with rescue medication over the course of the clinical trial and within periods: until treatment week ≤5, ≤11 and ≤14
timeFrame: Week 5, 11 and 14
Other outcomes:
measure: Number and severity of adverse events (AE)
timeFrame: Week 1 to 14
Locations:
city: Munich
country: Germany
facility: Klinikum Rechts der Isar (Zentrum für Interdisziplinäre Schmerztherapie)
state: Bavaria
Study officials:
References: